HIV / AIDS   

Gilead plays a central role in developing single tablet regimens – with one pill once a day, patients can take all of their medication in each dose.

Liver Diseases   

Our liver disease programs focus on expanding treatment options for chronic hepatitis B and C.

Oncology / Inflammation   

Our scientists are applying new knowledge about how cancers grow and spread to potentially enhance and improve cancer therapy.

Cardiovascular   

Our medicines aim to help patients with cardiovascular disease return to their daily activities, and we are exploring potential new indications.

Respiratory   

We research and develop treatments for serious respiratory conditions such as influenza, cystic fibrosis and other diseases of the lungs.

Other Therapies   

Gilead medicines treat severe fungal and parasitic infections, and address vision loss caused by degenerative eye diseases.

U.S. FDA Approves Zydelig®

Second Quarter 2014 Financial Results   

Access earnings press release, webcast link and slides for Gilead’s second quarter 2014 results. View materials.